Evotec (ETR:EVT) Shares Cross Below Fifty Day Moving Average – What’s Next?

Posted by on Aug 14th, 2026

Evotec SE (ETR:EVT – Get Free Report) shares passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of €4.28 and traded as low as €3.66. Evotec shares last traded at €3.85, with a volume of 709,422 shares trading hands.

Evotec Price Performance

The company has a market capitalization of $658.31 million, a price-to-earnings ratio of -3.84, a PEG ratio of 0.98 and a beta of 1.31. The company has a current ratio of 1.68, a quick ratio of 2.97 and a debt-to-equity ratio of 55.38. The company has a 50 day moving average price of €4.28 and a 200 day moving average price of €4.90.

Evotec Company Profile

(Get Free Report)

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic.

Featured Articles

Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.